San Diego-based Illumina Inc. has acquired Myraqa, a regulatory and quality consulting firm specializing in in vitro diagnostics, particularly companion diagnostics, Illumina announced.
The acquisition will bolster Illumina’s in-house capabilities for clinical readiness and help prepare for its next growth phase in regulated markets, the company said.
Myraqa is led by CEO Mya Thomae, who will lead Illumina’s regulatory strategy and execution, said Rick Klausner, chief medical officer of Illumina.
“With Myraqa, Illumina will continue to pave the way for the use of genomic technology, including next-generation sequencing, in regulated markets while also driving standards for use in the clinic,” Klausner said.
Myraqa’s team will continue to report to Thomae, who will report to Klausner, according to Illumina.
“We expect Mya and her team to complete existing programs and to continue to work with selected third parties on sequencing-based projects,” Klausner said.
Myraqa is based in Redwood Shores. It comprises leading experts in regulatory, quality, clinical, biostatistics and development.
Illumina is a developer, manufacturer and marketer of life science tools and systems for genetic analysis.